Several Nasdaq-listed names swung sharply in midday trading as second-quarter earnings surprised in both directions. Moderna plunged 25% a day after a vaccine-trial rally, while Nordson and Webull climbed on upbeat results and CrowdStrike slipped on a leadership departure.
Moderna gives back its vaccine-trial surge
Moderna plunged 25% one day after a skin-cancer vaccine trial win. The stock had soared 177% on those results. The trial, developed with Merck, tested the experimental vaccine in combination with Keytruda and met key goals in patients with high-risk or advanced melanoma whose detectable cancer had been fully removed through surgery.
CrowdStrike drops on CTO exit
CrowdStrike dropped 4% after Axios reported that chief technology officer Elia Zaitsev is leaving to start an AI-focused cyber venture fund called Cognition. Wolfspeed also declined, down 15% after quarterly revenue of $149.6 million came in just short of FactSet's $150 million consensus estimate. NetEase's U.S.-listed shares lost 5% after quarterly earnings missed analyst estimates.
Nordson and Webull beat expectations
Not every Nasdaq name fell. Nordson rose about 7% after the maker of coating and adhesive equipment raised its full-year guidance, now seeing adjusted earnings of $11.80 to $12 a share, up from an earlier forecast of $11.30 to $11.80, above a FactSet consensus call for $11.60. Webull gained more than 4% after second-quarter adjusted operating income totaled $62.6 million, above the $33.5 million analysts had estimated, on revenue of $198.8 million versus expectations of $183 million.
Source: CNBC
Trading involves risk.
Risk Disclaimer
